Enveda
Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases.
$311MSeries E
ParticipantDV
Digitalis Ventures
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $418M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionEpiBiologics
Develops bispecific antibodies for targeted degradation of extracellular proteins.
$107MSeries B
Role not disclosed